; and (2) if the supplemental application is approved, with respect to individuals aged 18 and older, such drug would not be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ). (b) Fee waiver The Secretary shall waive the fee under section 736(a)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379h(a)(1) ) with respect to a supplemental application that receives priority review under subsection (a). (c) Over-the-Counter availability Notwithstanding any other provision of law, with respect to individuals under age 18, a contraceptive drug that is eligible for priority review under subsection (a) shall be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ). 3. Empowering women to make their own health decisions (a) No limitations based on whether a drug is prescribed Section 9003 of the Patient Protection and Affordable Care Act ( Public Law 111–148 ), and the amendments made by such section, are repealed, and the Internal Revenue Code of 1986 shall be applied as if such section, and amendments, had never been enacted. (b) No limitations on health FSAs Sections 9005 and 10902 of the Patient Protection and Affordable Care Act ( Public Law 111–148 ) and section 1403 of the Health Care and Education Reconciliation Act of 2010 ( Public Law 111–152 ), and the amendments made by such sections, are repealed, and the Internal Revenue Code of 1986 shall be applied as if such sections, and amendments, had never been enacted.